Curebase and clinical research operating platform BEKHealth have entered a collaboration to expand patient access to decentralised clinical trials (DCTs).
The partnership will also aid research sponsors to detect candidates for trials, with improved efficiency and promptness.
Under the alliance, Curebase will use the artificial intelligence (AI)-driven, patient-matching technology platform of BEKHealth to identify potential trial subjects among patient populations that have been previously untapped.
It will also provide an opportunity to these patients, irrespective of their location.
This collaboration is based on the shared interest of the companies in providing access to trials to any patient, regardless of location, as well as expediting the launch of life-improving and life-saving therapies.
The platform of BEKHealth streamlines all medical data of patients in an EMR system, including handwritten notes from physicians, making it simpler to look for and find patients who match the protocol’s inclusion and exclusion criteria.
Curebase protocols will be run by BEKHealth throughout its network and match patients who meet the criteria, in order to offer a patient list, meeting a minimum of 90% of the criteria of the trial.
Curebase can then contact research sites with the trial details with the list of patients in their network who meet the requirements and are interested in taking part in a trial.
Curebase and BEKHealth will also partner to extend DCT into new treatment regions, including oncology while offering research prospects for sites that have so far not taken part in decentralised trials.
BEKHealth Partnerships and Strategy vice-president Halley Losekamp said: “In partnering with Curebase, we are furthering our mission to expand access to clinical research for all by literally bringing to the doorsteps of patients the opportunity to enrol in trials they might not have known about otherwise.
“We’re looking forward to working alongside Curebase to make more diverse types of clinical trial opportunities available to patients, no matter where they live, while at the same time easing the burden on research sites challenged with finding eligible participants.”
In June this year, Curebase and Portamedic entered a partnership to support DCTs with mobile phlebotomy services.